Valuation: Personalis, Inc.

Market Cap 1.75B 1.56B 1.46B 1.32B 2.49B 169B 2.51B 17.49B 6.8B 86.09B 6.57B 6.43B 277B P/E 2026 *
-15.2x
P/E 2027 * -17.4x
Enterprise Value 1.57B 1.4B 1.31B 1.19B 2.24B 152B 2.25B 15.72B 6.11B 77.36B 5.91B 5.78B 249B EV / Sales 2026 *
19.1x
EV / Sales 2027 * 15.2x
Free-Float
73.86%
Yield 2026 *
-
Yield 2027 * -
1 day-2.26%
1 week-1.78%
Current month-1.54%
1 month-6.80%
3 months+17.69%
6 months+143.62%
Current year+101.38%
1 week 15.84
Extreme 15.84
16.59
1 month 15.84
Extreme 15.84
17.35
Current year 4.96
Extreme 4.955
18.89
1 year 4.96
Extreme 4.955
18.89
3 years 0.89
Extreme 0.8906
18.89
5 years 0.89
Extreme 0.8906
21.69
10 years 0.89
Extreme 0.8906
53.46
Manager TitleAgeSince
Chief Executive Officer 57 01/03/2023
President 55 12/03/2026
Chief Executive Officer 65 30/12/2022
Director TitleAgeSince
Director/Board Member 79 30/04/2019
Chairman 76 16/05/2022
Director/Board Member 72 05/03/2021
Date Insider Type Main position Quantity % Market Cap. Importance
18/09/26 Sell

Chief Financial Officer

-2,931 0.0028%
18/09/26 Sell

Chairperson

-3,998 0.0038%
18/09/26 Sell

Chief Executive Officer

-7,459 0.0071%
Change 5-day change 1-year change 3-year change Capi.($)
-2.26%-1.78%+118.39%+1,235.83% 1.75B
-0.67%-1.62%+11.54%+23.91% 111B
-0.63%-0.09%+0.62%+76.10% 94.16B
-5.87%-2.70%+139.41%+829.37% 61.35B
-0.38%-6.09%-7.47%+56.12% 27.69B
-1.28%-3.88%+27.36%+85.70% 25.63B
+0.99%+0.69%+12.56%+55.24% 25.03B
+1.02%+2.47%-14.42%-3.18% 21.09B
-0.39%+0.21%+27.33%+325.75% 20.89B
+1.93%-1.25%-2.71%+35.91% 16.78B
Average -0.75%-0.63%+31.26%+272.07% 40.57B
Weighted average by Cap. -1.16%-0.23%+27.44%+185.74%

Financials

2026 *2027 *
Net sales 82.47M 73.25M 68.52M 62.14M 117M 7.95B 118M 824M 320M 4.05B 310M 303M 13.04B 109M 97.02M 90.77M 82.31M 155M 10.53B 156M 1.09B 424M 5.37B 410M 401M 17.27B
Net income -115M -102M -95.64M -86.73M -164M -11.09B -165M -1.15B -447M -5.66B -432M -423M -18.2B -102M -90.55M -84.72M -76.82M -145M -9.82B -146M -1.02B -396M -5.01B -383M -374M -16.12B
Net Debt -178M -158M -148M -134M -252M -17.11B -254M -1.77B -690M -8.73B -667M -652M -28.08B -91.04M -80.86M -75.65M -68.6M -129M -8.77B -130M -909M -353M -4.47B -342M -334M -14.39B
Projected Income Statement - Annual - Personalis, Inc.
Logo Personalis, Inc.
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Employees
260
Date Price Change Volume
06/10/26 US$16.03 -2.26% 5,656,274
05/10/26 US$16.40 +0.74% 1,702,462
02/10/26 US$16.28 +0.68% 1,139,121
01/10/26 US$16.17 -0.68% 1,659,831
30/09/26 US$16.28 -0.43% 984,127
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Ratings Surperformance© - Personalis, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
16.03USD
Average target price
15.44USD
Spread / Average Target
-3.70%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Personalis, Inc.
  1. Stock Market
  2. Stocks
  3. PSNL Stock